Know Cancer

or
forgot password

A Phase II Trial of ICE Chemotherapy Followed by High Dose BEAM Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients >= 60 Years Old With Refractory or Relapsed Intermediate Grade Non-Hodgkin's Lymphoma


Phase 2
60 Years
N/A
Not Enrolling
Both
Lymphoma

Thank you

Trial Information

A Phase II Trial of ICE Chemotherapy Followed by High Dose BEAM Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients >= 60 Years Old With Refractory or Relapsed Intermediate Grade Non-Hodgkin's Lymphoma


OBJECTIVES:

- Assess the efficacy and toxic effects of carmustine/etoposide/melphalan (ICE)
chemotherapy followed by peripheral blood progenitor cell transplantation in patients
with refractory or relapsed intermediate grade non-Hodgkin's lymphoma.

- Assess the ability of the ICE chemotherapy regimen, in conjunction with filgrastim, to
mobilize peripheral blood stem cells.

OUTLINE: This is a descriptive pilot study.

Patients receive 3 cycles of induction chemotherapy with ifosfamide, carboplatin, and
etoposide (ICE). Each cycle is given at least 14 days apart. Patients receive etoposide IV
on days 1 through 3. Carboplatin and ifosfamide with mercaptoethane sulfonate is given IV
over 24 hours on day 2.

During cycles 1 and 2, patients receive filgrastim (G-CSF) SC every 6 hours beginning on day
1 and continuing until the desired absolute neutrophil count (ANC) is attained.

Patients receive at least 24 hours of rest before PBPC infusion on day 0.

Following cycle 3, G-CSF is given SC beginning on day 6 and continuing until completion of
PBPC collection. However, bone marrow will be harvested if an insufficient number of stem
cells are collected after 5 leukaphereses.

Patients with residual disease limited to 2 sites receive radiation therapy twice a day
within 2 weeks prior to high dose BEAM chemotherapy with carmustine, etoposide, cytarabine,
and melphalan.

Patients receive carmustine IV on day -7. Etoposide and cytarabine are given IV every 12
hours on days -6 through -3. Melphalan is given IV on day -2.

G-CSF is administered every 12 hours beginning on day 1 and continuing until the desired ANC
is attained. If ANC is attenuated on day 21, patients undergo a repeat bone marrow biopsy
and receive filgrastim SC.

Patients are followed for 2 years posttransplant, then for 3 to 5 years at 4 month intervals
and every 6 months following the fifth posttransplant.

PROJECTED ACCRUAL: This study will accrue 30 patients for the duration of 2 years.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Primary refractory intermediate grade non-Hodgkin's lymphoma (NHL) OR

- Untreated relapsed intermediate grade NHL with no more than 1 extranodal site of
disease

- Biopsy proven relapse of diffuse large cell, diffuse mixed cell, diffuse small
cleaved cell (excluding mantle cell lymphoma), follicular large cell, anaplastic
large cell or immunoblastic NHL in recently attained complete response patients

PATIENT CHARACTERISTICS:

Age:

- 60 and over

Performance status:

- Karnofsky at least 80%

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Bilirubin no greater than 2.0 mg/dL unless there is a history of Gilbert's disease

Renal:

- No history of chronic renal insufficiency

- Creatinine no greater than 1.5 mg/dL or if greater than 1.5 mg/dL, then creatinine
clearance must be at least 60 mL/min

Cardiovascular:

- No myocardial infarction within the past 6 months

- No unstable angina or cardiac arrhythmias other than chronic atrial fibrillation

- Normal cardiac function required; MUGA scan or stress ECG ejection fraction at least
50% without significant wall motion abnormalities

Pulmonary:

- Adequate pulmonary function defined as DLCO at least 50% of predicted value when
corrected for patients hemoglobin and alveolar ventilation

Other:

- No medical illness unrelated to intermediate grade Non-Hodgkin's Lymphoma

- No uncontrolled infection

- No history of malignancy other than curatively treated cutaneous basal cell
carcinoma; carcinoma in situ of the cervix; axillary node negative breast cancer
without prior chemotherapy and disease free for more than 2 years; or prostate cancer
with surgery alone and disease free for more than 2 years

- No lymphoblastic lymphoma, small noncleaved cell lymphoma, CNS lymphoma or CNS
relapse of lymphoma

- Not HIV, HBV, and HCV positive

PRIOR CONCURRENT THERAPY:

- Concurrent enrollment in MSKCC protocol 96-17a allowed

Biologic therapy:

- Not specified

Chemotherapy:

- No more than 2 prior chemotherapy regimens

Endocrine therapy:

- Not specified

Radiotherapy:

- Not specified

Surgery:

- Not specified

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Outcome Measure:

Treatment-related toxicity

Safety Issue:

Yes

Principal Investigator

Craig Moskowitz, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000065505

NCT ID:

NCT00002982

Start Date:

January 1997

Completion Date:

Related Keywords:

  • Lymphoma
  • recurrent grade 3 follicular lymphoma
  • recurrent adult diffuse small cleaved cell lymphoma
  • recurrent adult diffuse mixed cell lymphoma
  • recurrent adult diffuse large cell lymphoma
  • recurrent adult immunoblastic large cell lymphoma
  • anaplastic large cell lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021